Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer

Shenkier, Tamara; Weir, Lorna; Levine, Mark; Olivotto, Ivo A.; Whelan, Timothy J.; Reyno, Leonard

doi:10.1503/cmaj.1030944

Cited by 95 publications

(53 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chemotherapy drugs are commonly used to inhibit metastases in breast cancer patients who undergo surgery (Markiewicz et al, 1996;Shenkier et al, 2004). However, the severe side effects (such as immunosuppression and myelosuppression) limit the long-term usage of chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Naringenin reduces lung metastasis in a breast cancer resection model

Qin

Jin

et al. 2011

Protein Cell

View full text Add to dashboard Cite

Metastasis is the main cause of death in cancer patients. To improve the outcomes of patients undergoing a surgery, new adjuvant therapies that can effectively inhibit metastases have to be developed. Studies have shown that flavonoid naringenin, a natural product that is mainly present in grapes and citrus, may contribute to cancer prevention. It has many advantages compared to traditional chemotherapeutic drugs, such as low toxicity. To determine whether naringenin can also inhibit metastases, a breast cancer resection model that mimics clinical situations was established. We found that orally administered naringenin significantly decreased the number of metastatic tumor cells in the lung and extended the life span of tumor resected mice. Flow cytometry analysis revealed that T cells displayed enhanced antitumor activity in naringenin treated mice, with an increased proportion of IFN-γ and IL-2 expressing T cells. In vitro studies further demonstrated that relief of immunosuppression caused by regulatory T cells might be the fundamental mechanism of metastasis inhibition by naringenin. These results indicate that orally administered naringenin can inhibit the outgrowth of metastases after surgery via regulating host immunity. Thus, naringenin can be an ideal surgical adjuvant therapy for breast cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Naringenin reduces lung metastasis in a breast cancer resection model

Qin

Jin

et al. 2011

Protein Cell

View full text Add to dashboard Cite

show abstract

“…Because of the low yield, cost, and distress associated with investigating detected abnormalities that are-for the most part-falsepositives, baseline systemic staging is neither performed nor recommended (54) before surgery and axillary staging in patients with early-stage breast cancer (56,98,99). In the patients with more advanced disease (such as LABC or inflammatory breast cancer), however, some evidence supports the use of systemic imaging staging at the diagnosis to rule out stage IV disease, which would significantly alter treatment options because of the high likelihood of distant metastases (30,100). Baseline systemic imaging staging needs to survey the chest, abdomen, pelvis, and bones and includes chest radiography or CT, abdominal ultrasound or CT, and bone scintigraphy.…”

Section: Distant (Systemic) Stagingmentioning

confidence: 99%

The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 1—Overview, Detection, and Staging

Lee¹,

Rosen²,

Mankoff³

2009

J Nucl Med

View full text Add to dashboard Cite

Breast cancer is the most common non-skin type of cancer and the second leading cause of cancer mortality in women. Advances in diagnosis and treatment have led to declines in mortality, despite an increase in breast cancer incidence. An advancing array of both local and systemic therapy options has led to increasingly individualized treatment. Imaging plays a key role in detecting breast cancer and directing its therapy. This continuing education article, part 1 in a 2-part series, provides a comprehensive review of current and future radiotracer imaging methods applied to breast cancer, in the context of breast cancer management strategies and other nonnuclear imaging methods. Part 1 of the review provides an overview of clinical and biologic considerations in breast cancer and covers radionuclide imaging for detection and staging. Part 2 will cover radionuclide imaging of breast cancer response to therapy, other clinical indications for radionuclide breast cancer imaging, and future directions, including molecular imaging.

show abstract

“…Popularity of BCS is increasing in the western world. [33], [34], [35], [36], [37], [38] The reasons supporting this theory are earlier diagnosis through mammographic screening, development of image-guided CNB and advent of state-of-the-art Radiotherapy Units. [34] MRM provides good locoregional control and still remains an important tool for managing breast cancer in India.…”

Section: Discussionmentioning

confidence: 99%

Epidemiological and Clinical Profile of Breast Cancer Patients at Kr Hospital, Mysore

Rangaswamy¹,

Vikas²

2018

jemds

View full text Add to dashboard Cite

BACKGROUNDCancer rates are set to increase at an alarming rate globally to 15 million new cases in the year 2020. Worldwide breast cancer is the most frequent cancer in women and represents the second leading cause of cancer death among women (after lung cancer). Presently, 75,000 new cases occur in Indian women every year. Immunological and histological management of breast cancer requires multidisciplinary treatment. The difference in management of breast cancer under the hands of surgical oncologist and general surgeons vary and need for aggressive planned neo-adjuvant chemotherapy by medical oncologist is needed. MATERIALS AND METHODSThis is a retrospective descriptive study hospital records of 104 patients admitted from October 2013 to October 2016 were used for study and data analysis. Study Design-A retrospective descriptive study. RESULTSThe average mean age of our female breast cancer patients was lower compared to the statistics of western world with at least one to two decades difference. A large percentage of patients were from rural setup and had longer duration of symptoms. Left side lump in the breast was the most common symptom. Screening by mammography and staging procedures such as bone scan, Computed Tomography (CT) scan and Magnetic Resonance Imaging (MRI) were sparsely used. The most common histology was infiltrating ductal carcinoma. CONCLUSIONModified radical mastectomy is considered gold standard in early breast cancer. Infiltrating ductal carcinoma was more commonly associated with positive lymph nodes compared to other histopathologies. Neoadjuvant chemotherapy was used mainly by clinical oncologists suggesting a more rational approach toward the management of breast carcinoma. [4] Epidemiology of breast cancer in India is very limited. Locally advanced breast cancer (LABC) constitutes more than 50% to 70% of the patients presenting for treatment. [4] Immunological and histological management of breast cancer requires multidisciplinary treatment. [3] The difference in management of breast cancer under the hands of surgical oncologist and general surgeons vary and need for aggressive planned neoadjuvant chemotherapy by medical oncologist is needed. Hence, this retrospective study was carried out to know the epidemiology, clinical presentation, risk factors and management strategies for breast cancer patients. 'Financial or Other Competing Interest': None. Submission 15-11-2017, Peer Review 12-01-2018, Acceptance 18-01-2018, Published 29-01-2018 Main, KGS Layout, Saraswati Nagar, Bangalore-40. E-mail: vikilaxman@gmail.com DOI: 10.14260/jemds/2018/153 KEYWORDS MATERIALS AND METHODSA total of 104 primary breast cancer patients admitted over a period of 3 years period (October 2013 -October 2016), in KR Hospital, Mysore were taken up for study. Post mastectomy patients outside KR Hospital were excluded. A detailed retrospective descriptive study analysis of patients was done and tabulated. The retrospective descriptive study information was collected from the medical reco...

show abstract

Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer

Abstract: Objective: To define the optimal treatment for women with stage III or locally advanced breast cancer (LABC).

Cited by 95 publications

References 71 publications

Naringenin reduces lung metastasis in a breast cancer resection model

Naringenin reduces lung metastasis in a breast cancer resection model

The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 1—Overview, Detection, and Staging

Epidemiological and Clinical Profile of Breast Cancer Patients at Kr Hospital, Mysore

Contact Info

Product

Resources

About